XML 73 R66.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 6 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Oct. 30, 2023 | Feb. 28, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Jul. 19, 2024 | Jul. 17, 2024 | Jun. 28, 2024 | Dec. 31, 2023
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
CVR derivative liability |  |  | $ 4,839 |  |  |  |  | $ 4,722
Purchase of property and equipment |  |  | 1,687 | $ 4,219 |  |  |  |
Investment, Type [Extensible Enumeration] |  |  |  |  | Other Long-Term Investments [Member] |  | Other Long-Term Investments [Member] |
Maximum |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Investment subscription amount |  |  |  |  |  |  | $ 4,200 |
Percentage of equity interest |  |  |  |  |  |  | 18.90% |
Subsequent Event |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Payment of initial investment |  |  |  |  |  | $ 1,700 |  |
Property and Equipment |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Purchase of property and equipment |  |  | 1,600 |  |  |  |  |
Research and Development |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Committed to allocate |  |  | $ 19,000 |  |  |  |  |
Contingent Value Rights Agreement |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Percentage of excess cash on dispositions net |  |  | 100.00% |  |  |  |  |
Excess amount retained from net proceeds related to disposition of assets |  |  | $ 1,000 |  |  |  |  |
Percentage of excess preapproved costs |  |  | 100.00% |  |  |  |  |
Distribution to CVR holders from asset sale proceeds |  | $ 200 |  |  |  |  |  |
Long-term CVR derivative liability |  | $ 4,500 |  |  |  |  |  |
CVR derivative liability |  |  |  |  |  |  |  | $ 4,700
Contributions closing payable amount | $ 1,100 |  |  |  |  |  |  |
Remaining outstanding balance |  |  | $ 300 |  |  |  |  |
F351 | Gyre Pharmaceuticals | Submission of the New Drug Application |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Obligation to pay in exchange for the intellectual property rights |  |  | 4,600 |  |  |  |  |
F351 | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Obligation to pay in exchange for the intellectual property rights |  |  | 1,200 |  |  |  |  |
F351 | Gyre Pharmaceuticals | NMPA's Approval of the NDA |  |  |  |  |  |  |  |
Commitments And Contingencies Disclosure [Line Items] |  |  |  |  |  |  |  |
Obligation to pay in exchange for the intellectual property rights |  |  | $ 7,000 |  |  |  |  |

X
- Definition CVR derivative liability noncurrent. + References No definition available. + Details
Name: | gyre_CVRDerivativeLiabilityNoncurrent
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments and contingencies disclosure. + References No definition available. + Details
Name: | gyre_CommitmentsAndContingenciesDisclosureLineItems
Namespace Prefix: | gyre_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Committed to allocate. + References No definition available. + Details
Name: | gyre_CommittedToAllocate
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent value rights derivative liability non current. + References No definition available. + Details
Name: | gyre_ContingentValueRightsDerivativeLiabilityNonCurrent
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contributions closing payable amount. + References No definition available. + Details
Name: | gyre_ContributionsClosingPayableAmount
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Distribution from asset sale proceeds. + References No definition available. + Details
Name: | gyre_DistributionFromAssetSaleProceeds
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Excess amount retained from net proceeds related to disposition of assets. + References No definition available. + Details
Name: | gyre_ExcessAmountRetainedFromNetProceedsRelatedToDispositionOfAssets
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investment subscription amount. + References No definition available. + Details
Name: | gyre_InvestmentSubscriptionAmount
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Obligation to pay in exchange for the intellectual property rights. + References No definition available. + Details
Name: | gyre_ObligationToPayInExchangeForTheIntellectualPropertyRights
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment of initial investment. + References No definition available. + Details
Name: | gyre_PaymentOfInitialInvestment
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of equity interest. + References No definition available. + Details
Name: | gyre_PercentageOfEquityInterest
Namespace Prefix: | gyre_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of excess cash on dispositions net. + References No definition available. + Details
Name: | gyre_PercentageOfExcessCashOnDispositionsNet
Namespace Prefix: | gyre_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of excess preapproved costs. + References No definition available. + Details
Name: | gyre_PercentageOfExcessPreapprovedCosts
Namespace Prefix: | gyre_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Remaining outstanding balance of agreement. + References No definition available. + Details
Name: | gyre_RemainingOutstandingBalanceOfAgreement
Namespace Prefix: | gyre_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column A)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.12-12A(Column C)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2 + Details
Name: | us-gaap_InvestmentTypeExtensibleEnumeration
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=gyre_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gyre_FThreeFiveOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gyre_GyrePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gyre_SubmissionOfTheNewDrugApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gyre_NDAPassesTheNMPAsReviewAndInspectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gyre_NMPAsApprovalOfTheNDAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |